Haemangiopericytomas (HPCs) are rare intracranial tumours. Until 1993 HPC was considered as an angioplastic variant of meningioma.1 The recently published WHO classification of central nervous system (CNS) tumours classifies HPCs as mesenchymal non-meningothelial tumours combined with solitary fibrous tumours (SFTs), graded 1–3, and it is likely that this nomenclature will further evolve in the future.2 While these are highly vascular tumours, they often present with mass effect.
